COVID-19 symptom severity predicts neutralizing antibody activity in a community-based serological study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 07 2022
18 07 2022
Historique:
received:
15
10
2021
accepted:
29
06
2022
entrez:
19
7
2022
pubmed:
20
7
2022
medline:
22
7
2022
Statut:
epublish
Résumé
Serological testing for SARS-CoV-2 IgG antibodies is used to assess their presence in blood samples from exposed individuals and provides a measure of the magnitude of immune response to infection. The measurement of neutralizing antibodies (NAbs) in particular provides information about the severity of prior infection and level of protective immunity against re-infection. Much of the work investigating the association between prior infection severity and NAb levels has been conducted among clinical populations, and less is known about this relationship in the general population. Accordingly, we utilize data from a large (n = 790) community-based cohort of unvaccinated, seropositive participants. We analyzed the association between NAb response, measured via surrogate virus neutralization assay, with patterns of symptoms and household exposure. Our results indicate no detectable NAb activity in 63.8% of the seropositive participants (n = 504). Those with detectable NAb levels demonstrated a positive relationship between NAb activity and both self-reported previous symptom severity and household exposure. These findings are significant in light of recent concerns about degree of protective immunity conferred by prior infection or vaccination, and we highlight the value of community-based research for investigating variation in immune response.
Identifiants
pubmed: 35851303
doi: 10.1038/s41598-022-15791-6
pii: 10.1038/s41598-022-15791-6
pmc: PMC9293881
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
12269Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001422
Pays : United States
Organisme : NIH HHS
ID : NIH 3UL1TR001422-06S4
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
JAMA. 2021 Apr 13;325(14):1467-1469
pubmed: 33646292
EClinicalMedicine. 2021 Aug;38:101018
pubmed: 34278286
N Engl J Med. 2021 Jul 1;385(1):90-92
pubmed: 33852796
Emerg Microbes Infect. 2020 Dec;9(1):1664-1670
pubmed: 32618497
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Sci Rep. 2021 Jan 21;11(1):2062
pubmed: 33479465
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
JCI Insight. 2021 May 10;6(9):
pubmed: 33755598
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
PLoS One. 2021 Mar 23;16(3):e0249090
pubmed: 33755688
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Sci Rep. 2021 Jul 28;11(1):15321
pubmed: 34321523
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
Emerg Microbes Infect. 2021 Dec;10(1):774-781
pubmed: 33830901
Cell Mol Immunol. 2021 Apr;18(4):936-944
pubmed: 33139905
N Engl J Med. 2021 Apr 8;384(14):1372-1374
pubmed: 33691060
Nat Commun. 2021 Apr 9;12(1):2117
pubmed: 33837204
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Science. 2020 Jun 5;368(6495):1060-1061
pubmed: 32414781
Open Forum Infect Dis. 2021 Jul 24;8(7):ofab244
pubmed: 34316503
Nature. 2021 Jul;595(7867):426-431
pubmed: 34126625